|
|
Blood, 15 May 2005, Vol. 105, No. 10, pp. 3972-3978.
Prepublished online as a Blood First Edition Paper on February 3, 2005; DOI 10.1182/blood-2004-09-3533.
 Previous Article | Next Article 
Submitted September 14, 2004
Accepted January 18, 2005
An anti-CD20-IL2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
Stephen D Gillies*, Yan Lan, Steven Williams, Frank Carr, Stephen Forman, Andrew Raubitschek, and Kin-Ming Lo
EMD Lexigen Research Center, Billerica, MA, USA
Biovation Ltd., Aberdeen, Scotland
Radioimmunotherapy, City of Hope National Medical Center, Duarte, CA, USA
* Corresponding author; email: sgillies{at}emdlexigen.com.
We have engineered an anti-CD20-IL2 immunocytokine (ICK) based on the Leu16 anti-CD20 antibody and have de-immunized both the V regions as well as the junction between the H chain constant region and IL-2. Mutations were made to remove potential T cell epitopes identified by in silico binding to MHC class II molecules. The resulting immunocytokine, DI-Leu16-IL2, retained full anti-CD20 activity as assessed by FACS analysis, and had enhanced ADCC effector function relative to the DI-Leu16 antibody or control anti-CD20 antibody (rituximab). In a SCID mouse model of disseminated, residual lymphoma, anti-CD20-IL2 immunocytokines based on Leu16 were far more effective at a dose of 0.25 mg/kg than anti-CD20 antibody given at 25/mg/kg, despite a shorter half-life of the ICK. Anti-CD20-IL2 was also far more effective than a control ICK targeted to an antigen with greatly reduced expression on Daudi tumor cells, or various combinations of anti-CD20 antibodies and IL-2. Anti-tumor activity of DI-Leu16-IL2 was shown to partially but not entirely depend on FcR binding, suggesting that ADCC and targeting of IL-2 both play roles in the mechanism of tumor clearance. Based on these animal models, DI-Leu16-IL2 could offer therapeutic potential for patients with CD20 positive lymphoma. Clinical trials are currently under development.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
Blood,
June 11, 2009;
113(24):
6161 - 6171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhou, W. Hu, and X. Qin
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Oncologist,
September 1, 2008;
13(9):
954 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. Pun Lee, C.-W. V. Lee, et al.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
Blood,
December 1, 2007;
110(12):
3959 - 3967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al.
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Cancer Res.,
March 15, 2007;
67(6):
2872 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
